Exploring molecular genetics of bladder cancer: lessons learned from mouse models

被引:37
作者
Ahmad, Imran [1 ,2 ]
Sansom, Owen J. [1 ]
Leung, Hing Y. [1 ,2 ]
机构
[1] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland
[2] Univ Glasgow, Inst Canc Sci, Glasgow G31 2ER, Lanark, Scotland
基金
英国医学研究理事会;
关键词
TRANSITIONAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; BETA-CATENIN ACTIVATION; FGFR3 MUTATION STATUS; IN-VIVO EVALUATION; PROGNOSTIC VALUE; URINARY-BLADDER; E-CADHERIN; HA-RAS; EPIGENETIC INACTIVATION;
D O I
10.1242/dmm.008888
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Urothelial cell carcinoma (UCC) of the bladder is one of the most common malignancies worldwide, causing considerable morbidity and mortality. It is unusual among the epithelial carcinomas because tumorigenesis can occur by two distinct pathways: low-grade, recurring papillary tumours usually contain oncogenic mutations in FGFR3 or HRAS, whereas high-grade, muscle-invasive tumours with metastatic potential generally have defects in the pathways controlled by the tumour suppressors p53 and retinoblastoma (RB). Over the past 20 years, a plethora of genetically engineered mouse (GEM) models of UCC have been developed, containing deletions or mutations of key tumour suppressor genes or oncogenes. In this review, we provide an up-to-date summary of these GEM models, analyse their flaws and weaknesses, discuss how they have advanced our understanding of UCC at the molecular level, and comment on their translational potential. We also highlight recent studies supporting a role for dysregulated Wnt signalling in UCC and the development of mouse models that recapitulate this dysregulation.
引用
收藏
页码:323 / 332
页数:10
相关论文
共 98 条
[1]   Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis [J].
Ahmad, I. ;
Patel, R. ;
Liu, Y. ;
Singh, L. B. ;
Taketo, M. M. ;
Wu, X-R ;
Leung, H. Y. ;
Sansom, O. J. .
CELL DEATH & DISEASE, 2011, 2 :e124-e124
[2]   β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation [J].
Ahmad, I. ;
Morton, J. P. ;
Singh, L. B. ;
Radulescu, S. M. ;
Ridgway, R. A. ;
Patel, S. ;
Woodgett, J. ;
Winton, D. J. ;
Taketo, M. M. ;
Wu, X-R ;
Leung, H. Y. ;
Sansom, O. J. .
ONCOGENE, 2011, 30 (02) :178-189
[3]   K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder [J].
Ahmad, Imran ;
Singh, Lukram Babloo ;
Foth, Mona ;
Morris, Carol-Ann ;
Taketo, Makoto Mark ;
Wu, Xue-Ru ;
Leung, Hing Y. ;
Sansom, Owen J. ;
Iwata, Tomoko .
DISEASE MODELS & MECHANISMS, 2011, 4 (04) :548-555
[4]  
BECCI PJ, 1981, CANCER RES, V41, P927
[5]   Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors [J].
Billerey, C ;
Chopin, D ;
Aubriot-Lorton, MH ;
Ricol, D ;
de Medina, SGD ;
Van Rhijn, B ;
Bralet, MP ;
Lefrere-Belda, MA ;
Lahaye, JB ;
Abbou, CC ;
Bonaventure, J ;
Zafrani, ES ;
van der Kwast, T ;
Thiery, JP ;
Radvanyi, F .
AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) :1955-1959
[6]   Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial [J].
Black, Peter C. ;
Dinney, Colin P. N. .
CANCER AND METASTASIS REVIEWS, 2007, 26 (3-4) :623-634
[7]  
Bohm M, 1997, INT J CANCER, V74, P291
[8]   Prediction of Progression of Non-Muscle-Invasive Bladder Cancer by WHO 1973 and 2004 Grading and by FGFR3 Mutation Status: A Prospective Study [J].
Burger, Maximilian ;
van der Aa, Madelon N. M. ;
van Oers, Johanna M. M. ;
Brinkmann, Anke ;
van der Kwast, Theodorus H. ;
Steyerberg, Ewout C. ;
Stoehr, Robert ;
Kirkels, Wim J. ;
Denzinger, Stefan ;
Wild, Peter J. ;
Wieland, Wolf F. ;
Hofstaedter, Ferdinand ;
Hartmann, Arndt ;
Zwarthoff, Ellen C. .
EUROPEAN UROLOGY, 2008, 54 (04) :835-844
[9]  
CAIRNS P, 1991, ONCOGENE, V6, P2305